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TaiwanAbstractBlood samples were collected from 101 untreated pulmonary
tuberculosis (TB) patients and 101 age- and sex-matched healthy
control subjects. TB patients had lower lymphocyte and a higher
monocyte counts than control subjects (p <0.0001 for both).
The seropositive rate of human herpesvirus (HHV) type 8
antibody was higher in patients (30/101) than in control subjects
(15/101) (p = 0.01). Antibody titres in patients also exceeded
those in control subjects (p 0.006). Lymphocyte and monocyte
counts between seronegative and seropositive subjects were not
different. Four patients were positive for HHV-8 DNA. The
study revealed a signiﬁcantly higher HHV-8 seroprevalence in
untreated pulmonary TB patients than in general population.
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com (T.-Y. Chu)IntroductionDepletion of CD4+ T-lymphocytes has been reported in pa-
tients with human immunodeﬁciency virus (HIV) infection or
tuberculosis (TB) [1,2]. Impaired interferon-γ production has
been demonstrated in peripheral blood mononuclear cells of
patients with either HIV infection or pulmonary TB. Aberrant
in vivo T cell activation has also been seen in both diseases [3].
There is a relatively high prevalence of human herpesvirus type
8 (HHV-8) infection in HIV-infected patients without Kaposi
sarcoma (KS) [4,5]. An association between TB and HHV-8
infection has not been previously described.MethodsBlood samples were collected from 101 pulmonary TB patients
(33 women and 68 men) before treatment; there were 101 age-
and sex-matched healthy control subjects. Mean age was 57.6
years (range 25–79 years). TB patients were identiﬁed in
Buddhist Dalin Tzu Chi Hospital. The healthy control subjects
were selected from persons admitted in the same hospital for
routine health examinations and proven not to have TB or
other major diseases. All subjects were negative for anti-HIV
antibodies. The study protocol was approved by the institu-
tional review board of Buddhist Dalin Tzu Chi Hospital. All
individuals gave their written informed consents for this study.
The lymphocyte and monocyte counts of peripheral blood
were analysed by an automated haematologic analyser (XE-
2100; Sysmex, Kobe, Japan). A commercial immunoﬂuores-
cence assay (IFA) kit (Advanced Biotechnologies Inc, Columbia,
MD) was used to detect HHV-8 antibodies against the lytic
antigens. Samples that displayed ﬂuorescence at a dilution of
1:40 were considered positive, according to the manufacturer’s
instructions. HHV-8 DNA was detected by polymerase chain
reaction ampliﬁcation of plasma DNA exactly as described
elsewhere [6].Diseases. Published by Elsevier Ltd. All rights reserved
TABLE 1. Lymphocyte and monocyte counts, and
seroantibody and DNA tests of HHV-8 in TB patients and
healthy control subjects
Characteristic TB Control p
Lymphocyte count, /μLa 1340 (172–3989)b 1837 (779–3205) <0.0001c
Monocyte count, /μLa 558 (74–1553)b 306 (141–609) <0.0001c
IFA positive rated 29.7% (30/101) 14.9% (15/101) 0.01e
Anti-HHV-8 titres





HHV-8 DNA 4 0 0.12g
HHV-8, human herpesvirus type 8; TB, tuberculosis; IFA, immunoﬂuorescence
assay.
aMean (range).
bLymphocyte and monocyte counts of three TB patients were unavailable.
ct test.




CMI Su et al. HHV-8 and tuberculosis 266.e6A χ2 or Fisher’s exact test was used to assess the signiﬁcance
of between-group differences in categorical variables. Differ-
ences in means of continuous variables between two groups
were analysed by t test. The comparison of anti-HHV-8 titres in
plasma between healthy control subjects and TB patients was
analysed by the Mann-Whitney test. Statistical signiﬁcance was
set at p <0.05. Statistical analyses were performed by SPSS
software, v12.0 (IBM, Armonk, NY).ResultsSeropositive rate and titres for HHV-8 antibody were signiﬁ-
cantly higher in pulmonary TB patients than in healthy control
subjects (Table 1). Seropositive rates did not differ between
men and women, and the mean ages between the seropositive
and seronegative subjects were also not different.
In our recent study of HHV-8 seroprevalence in patients
with end-stage renal disease, one of the two healthy control
subjects with IFA antibody titres of 1:160 was positive by the
speciﬁc enzyme-linked immunosorbent assay (ELISA) [7]. If the
cutoff point of the HHV-8 antibody titre was set at 1:160
(equivalent to the positivity with the ELISA method) in the
present study, the seropositivity was only marginally higher in
the TB study group than in healthy control subjects (6/101 vs.
0/101, p 0.059; Fisher’s exact test).
Plasma samples of three TB patients negative for HHV-8
antibody were found to contain HHV-8 DNA (544, 899 and
1011 copies/mL). It was also found in one of the 47 patients
positive for HHV-8 antibody (1415 copies/mL).
Mean lymphocyte count was much lower and monocyte
count was much higher in TB study group than in controlClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Insubjects (Table 1), but neither was signiﬁcantly different be-
tween seropositive and seronegative subjects. All of the TB
patients positive for HHV-8 were not found to have clinical
manifestations of HHV-8 infection, such as KS, primary effusion
lymphoma or Castleman disease.DiscussionHHV-8 seropositivity may vary depending on the type of
immunologic assay used. In general, IFAs are more sensitive
than ELISAs [8–10], and seroreactivity to lytic antibodies
greatly exceeds that to latent antibodies [11–13]. We used the
IFA to detect HHV-8 antibody against lytic antigen. Among
pulmonary TB patients, the observed seropositive rate and ti-
tres of HHV-8 antibody were signiﬁcantly higher than those in
healthy control subjects. The prevalence of HHV-8 infection in
pulmonary TB patients is lower than those reported in KS
patients (67–100%) [4,5,14]. However, it is comparable to
those reported in HIV-infected patients without KS (13–50%)
[4,5,14]. Our study suggests that pulmonary TB patients, like
HIV-infected patients, are vulnerable to HHV-8 infection. It
needs to be further investigated why rare KSs develop in pul-
monary TB patients compared with HIV-infected patients.
To our knowledge, the prevalence of HHV-8 infection in
pulmonary TB patients has not been studied before. In our
study, TB patients did show a signiﬁcantly higher HHV-8
prevalence; however, mean lymphocyte and monocyte counts
between seronegative and seropositive patients were not
signiﬁcantly different. High HHV-8 prevalence in pulmonary TB
patients appeared to be not associated with lymphocyte or
monocyte counts. Other causes need to be investigated.
The prevalence of HHV-8 infection tends to increase with
age [15], and KS also predominates in elderly men [16].
However, in the present study, among pulmonary TB patients
and healthy control subjects, HHV-8 prevalences between the
two sexes as well as the mean ages between seropositive and
seronegative subjects were not different.
In the present study, four pulmonary TB patients were posi-
tive for HHV-8 DNA. Of them, three were negative for HHV-8
antibody, and one was positive. HHV-8 DNA is rarely detected
in plasma, serum or buffy coat samples from individuals without
KS [12,17–19]. The underlying cause of this relative high prev-
alence of HHV-8 DNA in our TB patients was unclear. All the
subjects with seropositivity did not show overt clinical mani-
festations. Known cofactors that contribute to the development
of KS and other HHV-8-associated diseases in HHV-8-
seropositive individuals, including male sex and being more
immunocompromised, were not present in our seropositive
subjects. Whether there are additional cofactors remains elusive.fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 266.e5–266.e7
266.e7 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMIIn conclusion, the prevalence of HHV-8 infection in pulmo-
nary TB patients was signiﬁcantly higher than that in general
population and comparable to that in HIV-infected patients
without KS. It suggests that pulmonary TB patients are
vulnerable to HHV-8 infection. The relationships between
HHV-8 infection and TB infection and why rare KSs develop in
TB patients need to be further explored.
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